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Abstract
OBJECTIVES: The most appropriate strategy in the management of
right ventricular outflow tract (RVOT) reconstruction in patients with
tetralogy of Fallot early repair and late failure of right ventricle to pul-
monary artery continuity is still debated. This study addresses this issue
by evaluating retrospectively 12 years experience in this kind of recon-
struction, focusing exclusively on the performance of Hancock R© conduits.
METHODS: Data from 32 patients with an early repaired Tetralogy of
Fallot, 23 males and 9 females, who underwent 34 RVOT reconstruction (2
were reinterventions) with Hancock R© conduit at Fondazione Toscana “G.
Monasterio” Pediatric Cardiac Surgery department, Massa, Italy between
February 2003 and May 2015 were retrospectively reviwed. Median age
was 17, 6±11, 32 years (range 13 months to 41 years and 8 months), mean
BSA 1, 4 ± 0, 54m2 (0,34 m2 minimum and 2,12 m2 most), mean height
148, 1± 33, 6 cm (range 61 cm to 195 cm) and mean weight 49, 5± 26, 35
Kg (range 6,9 Kg to 96 Kg). The RV-PA peak gradient, RV mean pressure
and pulmonary regurgitation were measured before and after the surgi-
cal conduit implantation and on follow-up, in addition RV end-diastolic
volume index was measured, when feasible, before and after Hancock R©
implantation.
RESULTS: The early 30 days mortality was 6,25% and not related to
conduit failure. Complete follow-up was feasible in 27 patients and the
mean duration was 31, 6 ± 34, 42 months. The observed RV-PA peak
gradient means were 60, 4 ± 30, 06 mmHg preoperatively, 29, 1 ± 11, 48
mmHg postoperatively and 45, 3 ± 26, 02 mmHg on the last follow-up;
RV mean pressures were 53, 3±27, 73 mmHg preoperatively 41, 6±12, 71
mmHg postoperatively and 53, 6 ± 18, 8 mmHg on the last follow-up;
RV end-diastolic volume index means were 218, 3 ± 57, 94ml/m2 before
surgery and 126, 1 ± 14, 49ml/m2 after surgery. Conduit failure was ob-
served in 5 patients in which the the mean freedom from conduit failure
was 70, 56 ± 15, 02 months (mean age at failure 6, 86 ± 1, 78 years), in 4
of them percutaneous intervention were attempted (2 ballooning and 2
melody), 2 successful.
DISCUSSION: From our series the Hancock R© conduit can be actually
considered as a valuable solution for RVOT reconstruction in already op-
erated patients with ToF, considering good RV pressures and gradients
values even after up to 9 years of follow up.
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Chapter 1
Tetralogy of Fallot
“Robert D. Stewart, Constantine Mavroudis, and Carl L. Backer”
Tetralogy of Fallot – Pediatric Cardiac Surgery
Fourth Edition, Ed.: Wiley-Blackwell
1.1 Definition, Morphology and Nomenclature
Consensus definition of International Working Group for Mapping and
Coding of Nomenclatures for Pediatric and Congenital Cardiac disease:
Tetralogy of Fallot is defined as a group of malformations with biventricular
atrioventricular alignments or connections characterized by anterosuperior de-
viation of the conal or outlet septum or its fibrous remnant, narrowing or atre-
sia of the pulmonary outflow, a ventricular septal defect of the malalignment
type, and biventricular origin of the aorta. Hearts with tetralogy of Fallot will
always have a ventricular septal defect, narrowing or atresia of the pulmonary
outflow, and aortic override; hearts with tetralogy of Fallot will most often
have right ventricular hypertrophy.(Beland, Franklin, Jacobs, & et al., 2004)
The first syndrome description is from Niels Stentons’ published report, dated
back 1671 (Steno, 1671). Yet, we commonly refer to “A. L. E. Fallot” as first
original syndrome definition, which included the term “tetralogie” referring to
the four anatomical cornerstones’ syndrome he pointed out from autopsy speci-
mens: pulmonary artery stenosis, ventricle septal defect, rightward deviation of
the aorta’s origin and hypertrophy of the right ventricle (Fallot, 1888), as de-
scribed by Figure 1.1. Not uncommonly it’s also named Pentalogy of Fallot for
frequent recurrence of Atrial Septal Defect (ASD) (Abbott & Dawson, 1924),
but the most recent actual consensus definition is the one above.
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Figure 1.1: Comparison between a normal heart and an heart with Tetralogy
of Fallot [Reproduced from CDC web site:
http://www.cdc.gov/ncbddd/heartdefects/tetralogyoffallot.html ]
Nowadays It’s widely accepted that the four pathologic features origin sec-
ondarily to a common pathway of altered cardiac development, rather than
representing four “coincidence” errors of morphogenesis. It’s mainly involved,
as stated by Anderson et al.(Becker et al., 1975; Howell et al., 1990), the subpul-
monary infindibulum hypoplasia and narrowing, which may even appear vari-
able in length. They suggested the anterocephalad deviation of the infundibular
septum relative to septomarginal trabeculation as key feature for this event, how-
ever this was not a completely satisfactory unifying hypothesis. A more suitable
one does involves anterocephalad deviation of the outlet septum (muscular or
fibrous), but also requires abnormal relation of the septum to septoparietal
trabeculations, producing subpulmonary obstruction (Anderson & Weinberg,
2005). Anterocephalad malalignment and deviation of the infundibular septum,
relative to the limbs of septomarginal trabeculation, determine the Ventricle
Septal Defect (VSD), which is large, physiologically non restrictive, located di-
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rectly under aortic valve orifice and has three common morphological variants.
Deviation of outlet septum determine also varying degrees of Right Ventri-
cle Outflow Tract (RVOT) obstruction, defined as os infundibulum, which is
related to the hypoplasia of ventricular infudibulum and prominent septopari-
etal trabeculations that undergo progressive hypertrophy postnatally. Moreover
pulmonary valve morphology is usually abnormal, with thickened and immobile
leaflets, commissural fusion with or without tethering of leaflets to pulmonary
artery wall and bicuspid in more than half of the cases (Altrichter, Olson, Ed-
wards, & et al., 1989).
Other anatomical variants are the presence of one or more additional VSD
(5%) anteriorly on muscular septum (Dickinson, Wilkinson, Smith, & et al.,
1982) and variants of coronary artery anatomy, with the commonest as origin
of anterior descending coronary artery from the right one (Dabizzi et al., 1980;
van Son., 1995). Pulmonary atresia is present in 7% of patients with Tetralogy
of Fallot (ToF) (Chiariello et al., 1975) and in such setting there’s an impor-
tant distinction to be made between the presence or absence of Patent Ductus
Arteriosus (PDA). When PDA is present it’s most often the only source of pul-
monary blood flow and, even can be there a varying degree of pulmonary artery
hypoplasia, all or nearly all pulmonary segments are commonly supplied by
branches arborizing from left and right pulmonary arteries anyway. Instead, in
absence of PDA, varying amount of pulmonary parenchyma is supplied partially
or totally by Major Aorto-Pulmonary Collateral Arteries (MAPCAs), determin-
ing a condition with distinct clinical presentation, natural history and surgical
treatment strategies; an example of the latter is presented in Figure 1.2. How-
ever, it’s also important to consider that not all cases of pulmonary atresia with
VSD necessarily fall within the category of ToF.
ToF and it’s variants constitute nearly 10% of all Congenital Heart Diseases
(CHDs), representing the most common form between cyanotic CHDs with an
incidence of 421 cases per milion live births (Hoffman & Kaplan, 2002). Ge-
netic syndromes are identified in at least 20% of ToF and the most commonly
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Figure 1.2: Autopsy specimen of an heart with tetralogy of Fallot
with pulmonary atresia. The pulmonary supply is through multiple
systemic-to-pulmonary collateral arteries. The star shows the connection
between one of the collateral arteries and the intrapericardial pulmonary
arteries. [Reproduced from: “F. Bailliard and Robert H. Anderson” –
Tetralogy of Fallot – Orphanet J Rare Dis. 2009; 4: 2 ]
associated are DiGeorge syndrome, which is consequence of one from several
deletions on chromosome 22, and trisomy 21 (Michielon, Marino, Formigari, &
et al., 2006).
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1.2 Embriology∇
∇“Richard Jonas” – Tetralogy of Fallot with Pulmonary Stenosis
Comprehensive Surgical Management of Congenital Heart Disease
Second Edition, Ed.: CRC Press
1.2.1 Genetic Basis
Various genetic associations with Tetralogy of Fallot have been identified in the
last decade, including JAG1, NKX2.5 (Goldmuntz, Geiger, & Benson, 2001),
ZFPM2 and VEGF. However the most important association is chromosome
22 microdeletion, a chromosomal defect present in up to 40% of patients with
CHDs (Oskarsdo´ttir, Vujic, & Fasth, 2004), and specifically the 22q11.2 dele-
tion syndrome. This deletion determines defects in neural crest-derived tissues,
causing abnormal development of third and fourth brachial pouches, including
altered conotruncal development. In addition it can alters normal development
of thymus, affecting normal differentiation and tolerance of T-cells, and parathy-
roid glands, determining an immune dysfunction and hypocalcemia, features of
DiGeorge syndrome. Maeda et al. (Maeda, Yamagishi, Matsuoka, & et al.,
2000) found that 13% of patients with tetralogy had 22q11.2 deletion, with a
significantly higher prevalence in patients with pulmonary atresia and MAPCAs
than those with simple tetralogy with pulmonary stenosis. In addition, infants
with 22q11 deletion commonly present developmental delay and a increased life-
time risk of 20-30 times for schizophrenia (Bassett, Chow, AbdelMalik, & et al.,
2003).
1.2.2 Embryological Development of Tetralogy
To understand the embryology of ToF is crucial the comprehension of pulmonary
arteries development. Lung buds arise from the primitive foregut and carry
the arteries and veins, that invest the foregut, derived from systemic arterial
and venous circulations. Proximal mediastinal arteries, on the other hand, are
derived from the sixth dorsal aortic arches that coalescence with more distal
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vasculature. The proximal main pulmonary artery is formed by the division
of the original conotruncus and, by labeling specific embryo cells with green
fluorescent protein, it has been clarified the role of neural crest cells in the
development of conotruncal abnormalities, of which tetralogy is part.
Classic Theory of Development of ToF
The conotruncus (“bulbus” or “bulbus cordis”) is normally subdivided, through
a process of spiral septation, into two relatively equally sized vessels, namely
the aorta and the main pulmonary artery (Pexieder, 1995). In case of unequal
septation process the main pulmonary artery may become hypoplastic relatively
to the aorta. Other points of stenosis may be represented by the transition
point between main pulmonary artery and its branches, where the conotruncus
is in continuity with the dorsal aorta, and more distally the junction of the sixth
dorsal aorta with peripheral pulmonary vasculature, where can develop multiple
points of stenosis.
Van Praagh’s Theory of the Embriology of ToF
Van Praagh et al. postulated that the ToF represent the consequence of a
single defect, namely underdevelopment of subpulmonary conus (Van Praagh,
Van Praagh, Nebesar, & et al., 1970). Usually the subpulmonary conus, or
infundibulum, is a tube of muscle which normally lifts the pulmonary valve
superiorly, anteriorly and leftward, away from the other three valves that are
united by a single fibrous skeleton. When the subpulmonary infundibulum is
underdeveloped the aortic valve lies more anteriorly, superiorly and rightward
relative to the pulmonary valve than usual and besides the infundibulum has a
narrower lumen, causing less blood streaming trough the pulmonary valve and
main trunk which becomes hypoplastic.
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1.3 Presentation and Diagnosis
ToF is a common (Hoffman & Kaplan, 2002) cyanotic CHDs, however only a
slight number of patients present with deep cyanosis in neonatal period after
the closure of PDA and, in the other hand, there is a group of acyanotic ToF
patients, with normal oxygen saturation level and even signs of pulmonary over-
circulation if the stenosis is mild. More commonly there is a mild desaturation
of 80-90% depending on PDA presence and degree of pulmonary stenosis.
Infants with severe cyanosis have severe pulmonary valve stenosis or even
atresia, but they can remain undiagnosed until several days to weeks after birth
until PDA closure because of cyanosis absence, moment of clinical presenta-
tion. If PDA patency cannot be re-established at clinical presentation with
prostaglandines, it represents an emergency surgical situation to establish ade-
quate pulmonary blood flow.
The most common natural progression of acyanotic or mildly ToF patients is
the gradual baseline reduction of saturation with progressive Right Ventricular
Hypertrophy (RVH) and subvalvolar stenosis. Therefore, close-up follow-up of
these patients it’s crucial for an appropriate timed intervention before the de-
velopment of severe cyanosis. Despite their usual mild or absent cyanosis these
patients can develop episodes of profound hypercyanosis, also called TET spells,
as consequence of dynamic relative changes in pulmonary and systemical resis-
tance which leads to right to left shunting, through the VSD, downing saturation
well below 50%. The most popular causal hypothesis for these events, though
unproven, is an infundibular muscle spasm leading to a dynamic increasing of
subvalvular obstruction with resulting right-to-left shunt through VSD.
1.3.1 Clinical Exam
Infant present with varying degree of cyanosis, from mild pallor to marked
cyanosis, which eventually results in clubbing, that hence can be seen only
7
in advanced cases.
Auscultation. Reveals systolic murmur from RVOT obstruction, which
can soften or disappear during TET spells because of reduced flow through the
obstruction, while the VSD is not a source, or just a mild one, of murmur for
its large size. II tone splitting is not appreciable due to a small and abnormal
valve paired with low pulmonary pressures, which cause absence of the valve
closing sound.
1.3.2 Instrumental Studies
Chest X-Ray. Shows classic “boot shaped” heart, from RVH and small pul-
monary arterial knob, together with dark lung fields due to relative hypoperfu-
sion. In up to 1/4 of patients is also evident a right sided aortic arch.
Figure 1.3: Typical radiographic boot-shaped heart in a child with ToF (Case
courtesy of Dr Alexandra Stanislavsky, Radiopaedia.org, rID: 13349)
Electrocardiography. Shows marked RVH and right axis deviation,
but both are neither specific nor diagnostic.
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Echocardiography. Coupled with Doppler study provides a complete eval-
uation of ToF anatomy (Dadlani, John, & Cohen., 2008; Gatzoulis, Soukias, Ho,
& et al., 1999) and RVOT gradients estimation (see Figs. 1.4 and 1.5). Cardiac
Figure 1.4: Echocardiographic still frame of a modified parasternal long axis
view in patient with ToF demonstrates the large ventricular septal defect,
aortic override, and right ventricular hypertrophy.
[Reproduced from: “F. Bailliard and Robert H. Anderson” – Tetralogy of
Fallot – Orphanet J Rare Dis. 2009; 4: 2 ]
Figure 1.5: (a). Echocardiographic still frame of a slightly modified
parasternal short axis evidence significant hypoplasia of the pulmonary trunk
and the pulmonary arteries, which result from the anterocephalad deviation of
the outlet septum. (b) Doppler has been used, and demonstrates turbulence
and acceleration of the flow of blood in the right ventricular outflow tract.
[Reproduced from: “F. Bailliard and Robert H. Anderson” – Tetralogy of
Fallot – Orphanet J Rare Dis. 2009; 4: 2 ]
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Ultrasound (US) is also reliable in determining the coronary pattern in majority
of cases (Need, Powell, del Nido, & et al., 2000) and it’s powerfully increasing its
prenatal diagnosis capability (Tongsong et al., 2005) even if there’s no evidence
of benefit in long-term survival with in-utero diagnosis (Lee, Smith, Comstock,
& et al., 1995). Three-dimensional echocardiography appear to be an important
modality for long-term follow-up for morphological and functional changes in
patients with repaired ToF (Kjaergaard, Petersen, Kjaer, & et al., 2006).
Catheterization. It is not currently required in majority of infants before
reparative surgery, unless an unclear anatomy of pulmonary artery branches is
present or to confirm the origin of the anterior descending coronary from the
right coronary artery.
Computed Tomography (CT), Cardiac Magnetic Resonance (CMR) and
Magnetic Resonance (MRI).
Figure 1.6: (a). Magnetic resonance image of the heart in an infant with
tetralogy of Fallot. This image shows a large ventricular septal defect and
right ventricular hypertrophy. Descending aorta is on the right.
[Reproduced from: “S. Bruce Greenberg, Bernard D. Coombs, Robert M.
Steiner, Eugene C. Lin and Justin D. Pearlman” — Medscape website:
http://emedicine.medscape.com/article/350898-overview ]
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CT and MRI are useful before the complete repair to evaluate pulmonary
artery and aortic arch anatomy and to delineate coronary artery abnormali-
ties. CMR is the most reliable emergent instrument for long-term evaluation
of patients with repaired ToF for it’s effective quantification ability of Right
Ventricle (RV) volume and function and pulmonary regurgitant fraction, even
superior to cardio-US (Geva et al., 1998; Roest et al., 2002; van-den Berg et al.,
2007). It’s measures are becoming the benchmark for reintervention, especially
for pulmonary valve insertion or replacement (Therrien et al., 2005; Knauth et
al., 2005).
1.4 Medical Management
There is no long-term medical management available for ToF and the only defini-
tive treatment of choice is the surgical repair; however there are several medical
adjuncts available.
The most important of medical treatments available is the use of Prostaglan-
dine E1 (PGE1) to maintain ductal patency in profoundly cyanotic neonates
with ToF (Elliott, Starling, & Neutze, 1975). It’s administered as continuous
intravenous infusion at rate of 0, 01− 0, 1µg/Kg/min to maintain an adequate
patency of the duct until surgical repair or a surgical systemic to pulmonary
shunt are established. However, the use of PGE1 is limited the first week of life,
since in infants presenting after this period its administration will less likely
open the duct, with success rate being very low after 2 weeks of life. The main
adverse effect of PGE1 infusion is apnea, which often requires endotracheal in-
tubation and mechanical ventilation.
Other medical treatments aim to prevent or treat “TET spells”. Beta-
blockade are used by some cardiologists to theoretically prevent the incidence
of spasm of infundibular muscle, however there is conflicting evidence regarding
the effectiveness of this therapy (Cumming & Carr, 1966; Garson-Jr, Gillette,
& McNamara, 1981). The principal side effect of their prolonged use in patients
with ToF is an increased need of inotrope use and temporary pacing after sur-
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gical repair (Graham, Bandisode, Bradley, & et al., 2008), an evidence which
favour an earlier surgical correction for patients with paroxysmal spells. Acute
medical management for an hypercyanotic patient include oxygen supplement,
sedation, volume resuscitation and phenylephrine, an alpha-agonist that de-
termines direct vasoconstriction, causing an increase in systemic resistance, to
which follows an increment in pulmonary blood flow as result (Nudel, Berman,
& Talner, 1976; Tanaka, Kitahata, Kawahito, & et al., 2003). In patients who
require such intervention an early surgical repair or palliation is mandatory.
1.5 Surgical Repair
Surgical timing is still debated because of two issues regarding neonates with
ToF. The first addresses the preference in symptomatic neonates between direct
early repair of the defect, regardless of size or age, and the choice of palliation
before correction in selected patients below a certain age or size. The second
relates to acyanotic neonates and young infants and the necessity or not to re-
pair their defect at diagnosis.
Proponents of early repair consider rational this approach since shrinks the
time exposure of cyanosis, reducing a possible neurological distress development,
the entity of RVH and an aﬄiction in pulmonary artery and alveolar develop-
ment; moreover a palliation procedure means, by definition, the necessity of a
future re-intervention for the patient (Jonas, 2009). This choice would be fa-
vored by the possibility to perform early operations with low mortality (Derby
& Pizarro, 2005; Di Donato, Jonas, Lang, & et al., 1991; Hennein, Mosca, Urce-
lay, & et al., 1995; Kolcz & Pizarro, 2005; Parry, McElhinney, Kung, & et al.,
2000; Pigula, Khalil, Mayer, & et al, 1999; Reddy, Liddicoat, McElhinney, &
et al., 1995; Tamesberger, Lechner, Mair, & et al., 2008). However in contrast,
an increased morbidity, requirement of inotropes and a prolonged mechanical
ventilation after very early repair have also been reported (Kanter, Kogon, Kir-
shbom, & et al., 2010; van Dongen, Glansdorp, Mildner, & et al., 2003), as well
as high rates of early re-interventions in infants who undergo primary repair
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under 1 month of age (Hirsch, Mosca, & Bove, 2000).
Advocates of selective staged management of neonates and infants with ToF
focuses on the negative effects of both transventricular approach for the closure
of the VSD and the homografts or transannular patch use in very young patients,
in which either are really common. Effectively, the reports evidence a use of ho-
mografts or transannular patch in patients under 3 months of age over 50% (van
Dongen et al., 2003; Gustafson, Murray, Warden, & et al., 1988), which even
ranges from 84-100% in true neonates with less than 1 month (Hennein et al.,
1995; Kolcz & Pizarro, 2005; Tamesberger et al., 2008; Hirsch et al., 2000), and
a majority of VSD repairs via a transventricular approach. Staged repair per-
mits to avoid the transventricular approach and often preserves pulmonary valve
function, and this outweighs, for the supporters of this strategy, the necessity
to delay the primary repair. This explains why transatrial-transpulmonary ap-
proach with selective shunting in symptomatic neonates is still advocated with
excellent results (Fraser-Jr, McKenzie, & Cooley, 2001; Karl, Sano, Pornvili-
wan, & et al., 1992; Stewart, Backer, Young, & et al., 2005). Transatrial-
transupulmonary approach compared with transventricular approach reduces
incidence of RV arrhythmias and improve both RV function (Stellin, Milanesi,
Rubino, & et al., 1995) and valve-sparing techniques feasibility in over 80% of
patients (Stewart et al., 2005). Valve spearing usefulness is shown by the fact
that, even significant pulmonary regurgitation caused by transannular patch of-
ten evidence a good long-term tolerance (considering symptoms (Bacha, Scheule,
Zurakowski, & et al., 2001) and overall mortality (Kirklin, Kirklin, Blackstone, &
et al., 1989)), the Pulmonary Insufficiency (PI) eventually increases arrhythmia
incidence and risk of Sudden Cardiac Death (SCD) and decreases right ventricu-
lar function (Gatzoulis, Balaji, Webber, & et al., 2000; Horneffer, Zahka, Rowe,
& et al., 1990; Ilbawi, Idriss, DeLeon, & et al., 1987; Marie, Marcon, Brunotte,
& et al., 1992).
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1.5.1 Palliative Procedures
Blalock-Taussig Modified. The most commonly palliative procedure ex-
ecuted, that has supplanted the classic Blalock-Taussig shunt (de Leval, McKay,
Jones, & et al., 1977). It’s normally performed trough median sternotomy, even
some surgeons still approach via thoracotomy, since it allows the use of car-
diopulmonary bypass in case of hemodynamic collapse or severe hypoxia (even
the majority are performed without it), allows examination of coronary anatomy
and avoids multiple points of incision after complete repair for the patient.
The relative comfort in performing re-sternotomy developed nowadays has min-
imized the rationale of avoiding sternotomy for Modified Blalock-Taussig Shunt
(MBTS).
The technique consist in the anastomoses of a 3,5 or 4mm Gore-Tex shunt
end to side to innominate artery or subclavian artery (Odim, Portzky, Zu-
rakowski, & et al., 1995) and to the homolateral branch pulmonary artery,
typically on the opposing side of the aortic arch, followed by the ligation of the
ductus arteriosus (See Fig. 1.7). Duct ligation confirms the adequacy of the
shunt and decreases the chance of branch pulmonary artery coarctation that
can accompany the natural constriction of the duct.
Other Procedures. A transannular patch without VSD repair is performed
in small infants with very small pulmonary arteries and it has been reported
with success even if reserved for extreme situations (Korbmacher, Heusch, Sun-
derdiek, & et al., 2005; Seipelt, Vazquez-Jimenez, Sachweh, & et al., 2002).
RVOT and pulmonary valve percutaneous balloon plasty and stenting have also
been reported; it has shown to be helpful in very small patients and propo-
nents have also evidenced growth of the branch pulmonary arteries (Laudito,
Bandisode, Lucas, & et al., 2006; Wu, Wang, Lee, & et al., 2006). However
this procedure also demonstrated that effective relief of stenosis determines an
irreversible damage to the pulmonary valve (Dohlen, Chaturvedi, Benson, & et
al., 2009).
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Figure 1.7: Schematic diagram of MBTS via sternotomy approach. RSA
indicates right subclavian artery; RSV, right subclavian vein; SVC, superior
vena cava; RPA, right pulmonary artery; RA, right atrium; PA, pulmonary
artery; Ao, aorta; LCC, left common carotid artery; LSA, left subclavian
artery; and Innom.a., innominate artery.
[Reproduced from: “Johan Odim, Michael Portzky, David Zurakowski, et al.”
– Sternotomy Approach for the Modified Blalock-Taussig Shunt – Circulation
November 1, 1995 vol. 92 no. 9 256-261 ]
1.5.2 Complete Repair
Anesthetic induction in patients with ToF is concerning since it causes systemic
vascular dilatation with an exacerbation of right-to-left shunting, possibly lead-
ing to profound hypoxia and risk of hemodynamic collapse. Crucial basic prin-
ciples include maintaining adequate volume status with an hemoglobin level of
at least 10mg/dl, use of high inspired oxygen level and avoidance of inhalational
agents since they have a significant vasodilatory effect. Use of intravenous agents
minimize the undesiderated vasodilatation. Transesophageal echocardiography
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should be performed, if feasible for patient size, in every patient and should be
interpreted by a pediatric cardiologist.
Median sternotomy is performed and the size of the thymus noted before its
excision to exclude the association with DiGeorge syndrome. If a prior shunt
was performed it’s isolated after systemic heparinization and aortic and bicaval
cannulaton. Cardiopulmonary Bypass (CPB) is initiated with moderate hy-
pothermia (28◦C) and if the shunt is present it’s ligated proximally and distally
and divided to avoid any future tending of the branch pulmonary artery. If
the pulmonary artery is narrowed at the shunt site then the shunt is excised
from the pulmonary artery and an autopericardium patch is used to perform a
patch augmentation. A left ventricular vent is inserted trough the right superior
pulmonary vein, the aorta is cross-clamped and an anterograde cold-blood car-
dioplegia, for short lasting interventions, or custodiol cardioplegia, for long pro-
cedures, is delivered trough a cardioplegia cannula inserted into the aortic root.
For the cold-blood cardioplegia only an every 15-20 minutes re-administration,
or earlier at any sign of cardiac activity, is necessary. A topical saline solution
slush is placed together with the cardioplegia into the heart. Cavae are snared,
a medial right atriotomy is made (Hirsch & Bove, 2003) and RVOT examined.
Any endocardial fibroelastic tissue, which represent areas of turbulent flow, is ex-
cised as well as hypertrophyc muscle bundles projecting from septomarginal and
septoparietal bands are divided and partially excised, together with any smaller
trabecular muscles causing obstruction. Excessive resection must be avoided of
either RVOT septal portion, to prevent coronary arteries perforation, and RV
free wall, since this can cause coronary fistula from conal branches; moreover,
during the resection, the tricuspid subvalvar apparatus must be noted and pre-
served. The most of RVOT resection can be performed trough right atrium and
tricuspid valve but, if necessary, additional resection can be made trough pul-
monary valve. In presence of severe obstruction a small infundibular incision,
10-12mm in length and immediately below pulmonary valve annulus, may be
required to adequately resolve obstruction, which is closed with a thin-walled
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(0,4mm) Gore-Tex patch thereafter (Procedure illustrated in Figs. 1.8 and 1.9)
A longitudinal pulmonary arteriotomy is made and carried up to the two
anterior sinuses in presence of a trileaflet valve or into the lateral sinuses of a
vertically oriented bicuspid valve. In presence of an horizontally oriented bicus-
pid valve the incision is carried straight up to the ventricle-pulmonary artery
junction. A pulmonary valvotomy is performed to divide the typically partially
fused commissures to the level of arterial wall to provide a maximal opening
through the preserved annulus, then a probe is inserted to measure the size
and if it’s larger than -3 Z score the annulus is left intact. Pulmonary arte-
riotomy is then closed with a pantaloon pericardial patch, if the annulus has
not been incised, to maximize the size of pulmonary root and completely re-
lieve any supravalvar obstruction (Stewart et al., 2005) (Procedure shown in
Figure 1.10). Instead, when pulmonary annulus incision is performed, a simple
pericardial patch is used. Inspection of pulmonary branches orifices should be
done, being often stenotic in patients with ToF, and can be corrected with an
extension of pericardial patch, or with a separate one, into the branch.
The VSD is closed with a continuous horizontal mattress suture, using a
5-0 Ethibond, to place a glutaraldehyde fixed autologous pericardium around
the circumference of the defect. If autologous pericardium is not available then
bovine or porcine pericardium is used. Superiorly the suture must be placed
nearly the aortic annulus to avoid residual defects trough the trabeculations.
Inferiorly, between the muscle of Lancisi and tricuspid annulus, avoiding deep
suture bites is critical to avoid damage to Atrio-Ventricular (AV) node and bun-
dle of His. The patch is cut to slightly oversize the defect to avoid potential
subaortic narrowing which could results from anterior malalignment of VSD.
The Tricuspid valve is tested and the Patent Forame Ovale (PFO), which is
nearly always present, is closed primarily with a 5-0 Prolene suture, except in
neonatal period during which is left open. The right atrial incision is then closed
with two layers of running Prolene suture, the heart is carefully de-aired and
the cross-clamp removed.
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Figure 1.8: The surgical anatomy as viewed through a right atriotomy. The
free edge of the atrial wall is retracted with stay sutures. The location of the
VSD is denoted by the dashed line. (A) Stay sutures are placed in the septal
and anterior leaflets of the tricuspid valve for retraction. (B) The tricuspid
valve leaflets have been retracted and a single valve retractor is in place to aid
exposure. The inferior margin of the VSD can be seen superior to posterior
limb of the septal band.
Figure 1.9: (C) A dilator placed through the pulmonary annulus delineates the
course of the right ventricular outflow tract. The parietal extension of the
infundibulum is visible at the tip of the dilator. The parietal extension can be
resected at its origin from the infundibular septum, dissected up toward the
free wall, and amputated at the free wall. (D) Division of the obstructing
muscle bundles along the anterior limb of the septal band. (E) View through
the right atriotomy and tricuspid valve following patch closure of the VSD.
(AL, atrial leaflet; Ao, aorta; PA, pulmonary artery; RV, right ventricle;
RVOT, right ventricular outflow tract; SL, septal leaflet)
[Either reproduced from: “C. Mavroudis” – Tetralogy of Fallot – in Pediatric
Cardiac Surgery ]
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After separation from cardiopulmonary bypass direct measurement of right
and left ventricle pressure is made with a 21-gauge spinal needle attached to
a pressure transducing line. If the RV/Left Ventricle (LV) pressure ratio is
grater than 0,7 (Hirsch et al., 2000; Stewart et al., 2005) the transesophageal
echocardiography is assessed to evidence and level any residual obstruction. If
it’s predominantly at the annulus the CPB is recommenced and a transannular
patch is performed, while if it’s exclusively subvalvar only an infundibular patch
is created immediately below the annulus extending 10-12mm. Temporary atrial
and ventricular pacing wires are always placed, regardless of the rhythm, be-
cause of the high incidence of Juctional Ectopic Tachycardia (JET) following
the repair of the ToF.
Figure 1.10: (A) Pulmonary arteriotomy. (B) Autologous pantaloon
pericardial patch. (C) Completed pulmonary artery pantaloon patch.
[Reproduced from (Stewart et al., 2005)]
1.6 Surgical Results
1.6.1 Mortality
The morality rate for complete repair of ToF has sharply decreased from an
initial 40% (Lillehei, Cohen, Warden, & et al., 1955), to a 20% revealed between
1955-1960 at Mayo clinic (Murphy, Gersh, Mair, & et al., 1993) and reaching
a 4,9% from 1960 to 1982 at Stanford (Zhao, Miller, Reitz, & et al., 1985).
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However in that era the age of repair was older, with a mean of 12,2 years
considering a series of over 650 patients from 1958 to 1977 (Nollert, Dabritz,
Schmoeckel, & et al., 2003), and the advent of the neonatal surgery determined
a recrudescence in mortality levels (Nollert et al., 2003; Ebert & Turley, 1984;
Turley, Mavroudis, & Ebert, 1982; Barratt-Boyes & Neutze, 1973; Castaneda,
Freed, Williams, & et al., 1977). Nevertheless, improvements in the last three
decades in surgical technique, anesthetic management and perioperative care
let a dramatic reduction of mortality even for infant and neonatal ToF repair,
reaching nowadays even levels of 0,5% (Karl et al., 1992) and with a global of
0-3% (Derby & Pizarro, 2005; Kolcz & Pizarro, 2005; Parry et al., 2000; Reddy
et al., 1995; Tamesberger et al., 2008; Kanter et al., 2010; van Dongen et al.,
2003).
Long-term survival rate for patients with ToF is excellent, even for patients
operated in the earliest era, with a 30 years actuarial survival of 86-89% (Murphy
et al., 1993; Nollert, Fischlein, Bouterwek, & et al., 1997) that must be compared
to an expected rate of 96% of the control population matched for age and sex.
1.6.2 Morbidity
The most significant complications following ToF repair are arrhythmias, early
reoperation or catheter reintervention, residual VSD and heart block. Heart
block requiring pacemaker has an incidence of 0-2% and usually occurs late after
intervention (Friedli, 1999), and an early postoperative transient heart block is
a risk factor for the development of late heart block (Hokanson & Moller, 2001).
Others complications include phrenic nerve injury, chylothorax, delayed sternal
closure.
Early Reoperation and Reinterventions
The RV can tolerate the volume load of PI for a number of years, therefore the
reoperation for this reason is a rare early event, while is a significant one late af-
ter repair. Instead, the most common reason for an early reoperation after ToF
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repair is residual RVOT obstruction, which can be located at the infundibu-
lar, valvular or branch pulmonary arteries level, the latter often amenable of
catheter-based balloon plasty and/or stent placement. The incidence of reop-
eration in electively operated patients varies greatly among different patient
populations, spacing globally from 3-8% (Fraser-Jr et al., 2001; Tamesberger et
al., 2008) but reaching level as high as 30% in primary repair of symptomatic
neonates (Hirsch et al., 2000). When primary repair is compared with staged
repair no statistically significant difference has been revealed regarding freedom
from reoperation (Knott Craig, Elkins, Lane, & et al., 1998).
The amount of residual obstruction after initial repair, evidenced by RV/LV
pressure ratio, is directly related to incidence of reoperation, a study of the Uni-
versity of Alabama demonstrated that a ratio grater than 0,85 is a associated
with a 2,5 times increased risk of death and 7,5 risk of reintervention (Katz,
Blackstone, Kirklin, & et al., 1982).
Other indications for early reoperations include residual VSD, residual ASD,
RVOT aneurysm, severe tricuspid regurgitation, heart block, phrenic nerve in-
jury and chylothorax.
Arrhythmias and Sudden Death
Arrhythmias and conduction disturbances are important both for their preva-
lence and consequences, especially considering that SCD is the most common
cause of mortality late after ToF repair, most probably related to ventricular
arrhythmias (Gatzoulis et al., 2000).
In the early post-operative period the right bundle branch block is the most
common conduction disturb due to suture damage or RVOT incision and it in-
volves over 90% of patients when ventriculotomy is performed (Friedli, 1996);
while the complete heart block is relatively uncommon with a reported incidence
of 1-3% (Kolcz & Pizarro, 2005; Pigula et al., 1999; Tamesberger et al., 2008;
Kanter et al., 2010). Instead, the most common after repair early arrhythmia
is JET, which incidence varies greatly based on age at surgery and surgical ap-
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proach, but it’s grater when transventricular repair is performed (Pigula et al.,
1999) rather than transatrial/transpulmonary approach, spacing for the latter
from 12% (Stewart et al., 2005) to 6% (Fraser-Jr et al., 2001). JET can result
in major hemodynamic instability in the immediate postoperative period.
Late arrhythmias after ToF repair include both atrial and ventricular tachy-
cardias, with an evidenced global incidence of over 43% in a retrospective study
from The Alliance for Adult Research in Congenital Cardiology (20% atrial
and 15% ventricular arrhythmias) (Khairy, Aboulhosn, Gurvitz, & et al., 2010),
even this might be an overestimation in a selected population. The paroxysmal
Sopra-Ventricular Tachycardia (SVT) is the most common late type arrhyth-
mia, as a re-entry tachycardia with re-entrant circuits that can develop even in
atrial incision scars, with development risks as older age at surgery, tricuspid re-
gurgitation, right atrial enlargement and poor RV function (Khairy et al., 2010;
Harrison, Siu, Hussain, & et al., 2001; Roos-Hesselink, Perlroth, McGhie, & et
al., 1995; Le-Gloan, Guerin, Mercier, & et al., 2010; Wessel, Bastanier, Paul,
& et al., 1980). Ventricular arrhythmias instead include as risk factors older
age at repair, ventriculotomy, severe pulmonary regurgitation, poor right or left
ventricle function and elongated QRS duration (Gatzoulis et al., 2000; Harri-
son et al., 2001; Dietl, Cazzaniga, Dubner, & et al., 1994; Khairy, Landzberg,
Gatzoulis, & et al., 2004).
1.6.3 Long-term Complications Following Repair of
Tetralogy of Fallot
The major late complications represent a consequence of a disarrangement in
right ventricle physiology, specifically caused by volume overload, as a con-
sequence of pulmonary insufficiency, tricuspid regurgitation and any possible
residual shunt, together with pressure overload resulting from residual pul-
monary stenosis. The sequelae to this event might include RV disfunction,
ventricular arrhythmias including SCD, late LV disfunction and aortic aneurys-
mal dilatation and the long-standing PI is the primary etiology for their devel-
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opment. The cause of PI is directly related to the use of the transannular patch
and, even if some authors report a good long-term functional outcomes after
repair of ToF with the transannular patch (Bacha et al., 2001; Kirklin et al.,
1989), others have reported a deleterious effect of PI on the RV when more sen-
sitive measures are made (Roest et al., 2002; Horneffer et al., 1990), with severe
RV dysfunction evident at CMR even in asymptomatic patients (Roest et al.,
2002; Singh, Greenberg, Yap, & et al., 1998). Moreover, exercise testing shown
impaired functional status in ToF patients with long term PI (Horneffer et al.,
1990; Carvalho, Shinebourne, Busst, & et al., 1992), which is relieved, together
with RV function, after pulmonary valve late insertion (Discigil, Dearani, Puga,
& et al., 2001; Eyskens, Reybrouck, Bogaert, & et al., 2000; Warner, O’Brien,
Rhodes, & et al., 2003).
Pulmonary Valve Replacement
Pulmonary Valve Replacement (PVR) in patients with severe PI late after ToF
repair, has shown functional improvement in several reports, however correct
timing and effect of PVR still remain debated. In fact, while one study showed a
decrease from 23% to 9% in Ventricular Tachycardia (VT) after PVR (Therrien,
Siu, Harris, & et al., 2001), another demonstrated no difference in VT or SCD
incidence (Harrild, Berul, Cecchin, & et al., 2009); in addition the effect and
lasting of it on QRS duration is variable (van Huysduynen, van Straten, Swenne,
& et al, 2005; Oosterhof, Vliegen, Meijboom, & et al, 2007). Regarding RV the
PVR demonstrated an improvement both in function and size of RV (van Huys-
duynen et al., 2005; van Straten, Vliegen, Lamb, & et al., 2005), however the
gain was limited if the ventricle reached a critical size.
Considering all this variable outcomes there are no universally accepted indi-
cation for PVR, however most authors consider it an important late intervention
in patients with repaired ToF, unless executed too late in which the benefits be-
come limited. Geva and colleagues consider an indication the presence of any two
between: Right Ventricle End-Diastolic Volume index (RVEDVi) > 160ml/m2,
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Right Ventricle End-Sistolic Volume index (RVESVi) > 70ml/m2, Left Ven-
tricle End-Diastolic Volume index (LVEDVi) > 65ml/m2, RV ejection fraction
< 45%, RVOT aneurysm and clinical symptoms or signs (Geva, 2006).
The main technical modalities of PVR include: homograft replacement,
valved conduit replacement and orthotopic bioprosthetic valve insertion with cre-
ation of RVOT hood with Gore-Tex or heterograft pericardium (Champsaur,
Robin, Curtil, & et al., 1998; Chan, Fyfe, McKay, & et al., 1994; Homann,
Haehnel, Mendler, & et al., 2000).
Neurological Outcomes
Children with repaired ToF evidenced an inferior full-scale IQ than the general
age-matched population (Miatton, De-Wolf, Francois, & et al., 2007), however,
when they were stratified according to the presence of genetic abnormalities,
those without any defect had scores within normal ranges per age (Zeltser,
Jarvik, Bernbaum, & et al., 2008).
It has also been evidenced an higher incidence of stroke in adult patients
with repaired ToF compared with general population, even if no clear etiology
has been demonstrated (Chow, Amos, & Celermajer, 2005).
Aortic complications
Aortic valve and root complications late after ToF repair have been well doc-
umented; specifically Zahka and collegues noted a severe aortic regurgitation
incidence of 21% at 18 years from primary repair (Zahka, Horneffer, Rowe, &
et al., 1988). It has also been evidenced that it becomes in the childhood and
that it’s associated with high level of elastic fiber fragmentation in ToF patients
aorta (Chong, Wong, Chiu, & et al., 2006). This and other aortic parietal le-
sions present in ToF patients are responsible of aortic aneurism (Dimitrakakis,
Von-Oppell, Bosanquet, & et al., 2009) and dissection (Kim, Seo, Kim, & et al.,
2005) development late after ToF repair, but their interventional criteria are
similar to non-ToF patients (Crestanello, Cook, Daniels, & et al., 2010).
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Tetralogy of Fallot Surgical
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Chapter 2
Ventricular to pulmonary
artery conduits∞
∞“John Brown, Osama Eltayeb, Mark Ruzmetov, Mark Rodefeld, and Mark W. Turrentine”
Ventricular to Pulmonary Artery Conduits – Pediatric Cardiac Surgery
Fourth Edition, Ed.: Wiley-Blackwell
In infants with valve pathology surgical reconstruction is the primary goal in all
interventions because anatomy and physiology restoration using native tissues
permits growth and a potentially better long term outcome. However when
repair fails or is not feasible then valve replacement becomes the only available
option (Husain & Brown., 2007). This procedure in neonates, infants and chil-
dren is challenging because of the strict interrelation of valve pathology, patient
size and growth requirement.
Pulmonary valve is the most common valve replaced in congenital popula-
tion and RVOT reconstruction is performed in patients with CHD who present
discontinuity between RV and the branch pulmonary arteries or in whom sig-
nificant pulmonary stenosis or insufficiency is present. In 1964 Rastelli and
colleagues inserted the first Right Ventricle-to-Pulmonary Artery (RV-PA) con-
duit, a pericardial non valved tube, in a child with pulmonary atresia (Rastelli,
Ongley, Davis, & Kirklin., 1965), while in 1966 Ross and Somerville introduced
the aortic valved allograft for RVOT reconstruction (Ross & Somerville., 1966).
Extracardiac conduits now permit routine repair of CHD in which pulmonary
atresia or RVOT hypoplasia is involved. These lesions are part of complex CHDs
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including Tetralogy of Fallot with or without pulmonary atresia (the case we
studied), Truncus Arteriosus, Pulmonary Atresia or Stenosis with or without
VSD, Transposition of Great Arteries, certain subtypes of Double Outlet Right
Ventricle and Pulmonary Autograft Replacement in the Ross operation. Many
of these condition are corrected in neonates, the most challenging context for
any prothesis selected for RVOT reconstruction.
The porcine valve Dacron conduit was extensively used between 1970s and
early 1980s, but after, for a while, it had been abandoned due to late obstructive
complications related to the development of a neointimal peel within the tube
(Jonas, Freed, Mayer, & et al., 1985). Nowadays however it’s use is increasing
again and new trials and retrospective evaluation are performed. Aortic and
pulmonary cryopreserved allografts became the main choice for RVOT recon-
struction from mid 1980s to late 1990s, this favoured by the development of
cryopreservation techniques which improved considerably either durability and
availability of allograft. At present a wide range of valved conduits have been
introduced and the most notably are: aortic xenografts in Dacron tubes, stented
bovine pericardial or porcine xenografts in pericardial tubes, glutaraldehyde fixed
aortic and pulmonary roots, aortic and pulmonary allografts and bovine jugular
vein conduits (Forbess, Shah, Louis, & et al., 2001; Dearani, Danielson, Puga,
& et al., 2003; Sinzobahamvya, Wetter, Blaschczok, & et al., 2001; Tweddell,
Pelech, Frommelt, & et al., 2000; Chan et al., 1994; Bando, Danielson, Schaff,
& et al., 1995).
2.1 Monocusp Right Ventricular Outflow Tract
Reconstruction
Patients with ToF and significant pulmonary valve annulus or leaflet hypoplasia
historically have been treated in two distinct possible ways: transannular patch
or valved conduit insertion. Transannular patch relieves immediately RV hyper-
tension and enhances RV growth proportionally with patient growth, moreover
reoperation for RVOT stenosis is uncommon. However it determines a sudden
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hemodynamic conversion from an obstructed and pressure overloaded RV to
a volume overloaded RV, with the chronic volume overload which can lead to
a late biventricular dysfunction and Tricuspid Valve (TV) insufficiency, possi-
bly necessitating a pulmonary valve insertion (Feier, Collart, Ghez, & et al.,
2005; Wells, Arroyo-Jr, Bremner, & et al., 2002). Valved conduits have the
advantage of an immediate pulmonary valve competency and are particularly
useful for patients who present with a peripheral pulmonary stenosis or with
an elevated Pulmonary Vascular Resistance (PVres) (PVres > 4 Wood units).
Opposingly the main disadvantage of current conduits it’s the structural dete-
rioration caused by calcification, shrinkage and lack of growth which determine
early or late valve disfunction. However pulmonary allograft conduits remain
popular at present despite a freedom from reoperation of 50% at 5 years in
patients undergoing a non-Ross RVOT conduit insertion (Bando et al., 1995;
Wells et al., 2002).
An attractive alternative strategy is the concept of RVOT reconstruction with
a monocusp patch, which can have specific advantages in selected populations of
infants. A monocusp valve can be placed in any sized patient, being the patch
tailor-made to fit the RVOT after its enlargement with a transannular outflow
patch, is less expensive and usually last longer than a valved conduit in an infant.
The monocusp RVOT patch can be made with autologus or bovine pericardium
(Raanani, Yau, David, & et al., 2000; Discigil et al., 2001), allograft pulmonary
valve cusp (Gundry., 1999) or a Polytetrafluoroethylene (PTFE) membrane tra-
ditionally employed as pericardial substitute (Ando, Imai, Takanashi, & et al,
1997; Bogers, Roofthooft, Pisters, & et al., 1994; Yamagishi & Kurosawa, 1993;
Oku, Matsumoto, Kitayama, & et al., 1993; Turrentine, McCarthy, Vijay, & et
al., 2002b). Each material has proven a good immediate postoperative valve
competency and reduced early PI (Bogers et al., 1994; Oku et al., 1993; Tur-
rentine et al., 2002b; Gundry, Razzouk, Boskind, & et al., 1994).
In 1993 Yamagishi and Kurosawa and Oku and colleagues independently intro-
duced a readily 0.1mm PTFE pericardial membrane for monocusp construction
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and found it superior when compared to biologic leaflets materials. Clinical ap-
plication of this material in patients with ToF, in whom transannular patching
was necessary, permitted an improved RV perioperative function as demon-
strated by a lower postoperative central venous pressure, less need of postoper-
ative inotropic agents, less chest tube drainage and a decrease in hospital and
Intensive Care Unit (ICU) stay (Turrentine, McCarthy, Vijay, & et al., 2002a).
This material it’s now the authors (Brown, Eltayeb, Ruzmetov, Rodefeld, &
Turrentine., 2013) choice for monocusp construction in RVOT disorders, either
obstructive and regurgitant, and especially in infants undergoing primary ToF
repair and in whom transannular patching is necessary.
Construction of a pericardial or PTFE monocusp is simple, relatively in-
expensive and reproducible, while pulmonary allografts are considerably more
expensive and possibly difficult to fit adequately into the RVOT. The main po-
tential disadvantage of monocusp patches is a possibly quicker recurrence of PI
if the monocusp leaflet stick in open position, as has been reported with some
biologic monocusps (Bogers et al., 1994; Turrentine et al., 2002b; Gundry et
al., 1994), while recurrent stenosis at the monocusp valve level is rarely seen
with any type of material. The major PTFE-specific advantage is the absence
of in-growth of tissue and therefore a much longer lasting valve mobility and
function.
The monocusp insertion is a relatively standardized technique. It consists
in determining the length and width of monocusp membrane, which are usually
kept mildly redundant to guarantee coaptation to conal septum and/or residual
pulmonary leaflets tissue, followed by its sewn into the RVOT, together with
the sew of a second patch of 0,4mm PTFE across the entire RVOT into the pul-
monary artery with a second suture line. Specifically, in patients with an intact
pulmonary annulus its dimensions, following valvotomy, are measured with a
Hegar dilator and if the annular Z value is ≥ −2 then transannular patching
is not perfmormed. Instead, with a moderate hypoplasia (Z score <-2) or with
a postvalvotomy RVOT gradient >30mmHg and/or RV pressure >80% of sys-
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temic pressure the transuannular patch repair with a monocusp valve insertion
is performed (Entire procedure is shown in Figs. 2.1 to 2.6).
PTFE monocusp with separate RVOT patch has been demonstrated useful in
patients with ToF or with pulmonary atresia and VSD who require transannular
patch and in patients requiring a second RVOT procedure after a failed initial
conduit reconstruction. Referring to authors experience they have described a
well-functioning monocusp valve for a mean of 3–4 years in most patients, reach-
ing up to 10–12 years in some of them. The majority of patients developed a
pulmonary regurgitation as RVOT grew, however they didn’t observed recurrent
outflow obstruction at the leaflet level. Another important indication for PTFE
monocusp reconstruction is the primary allograft conduit failure since the posi-
tioning of a second conduit has been associated with an accelerated structural
failure (Wells et al., 2002). The only anticoagulant used after PTFE monocusp
positioning is aspirin with dose of 10mg/kg a day or 80mg/day as limit.
Several bicuspid PTFE reconstructions and a folding monocusp PTFE leaflet
have been recently introduced (Turrentine et al., 2002a; Brown, Ruzmetov, Vi-
jay, & et al., 2007) and early results seem promising, however longer follow-up
will be necessary to evaluate their durability.
Quintessenza and colleagues described a bicuspid RVOT outflow reconstruc-
tion (Quintessenza, Jacobs, Chai, & et al., 2010) and their early results at
3 years, with a 0.1 PTFE, are considerably better than those obtained with
0.6mm PTFE observed for 8 years. Nunn and colleagues described a folding
monocusp with 0.1mm PTFE and evidenced a lesser degree of RVOT regur-
gitation traded with an higher gradient at mid-term follow-up, respectively to
the simple horizontal monocusp (Nunn, Bennetts, & Onikul., 2008). Morell and
colleagues described a PTFE tube with a bicuspid PTFE valve constructed into
the conduit with satisfactory results even after a short (less than 1 year) follow
up.
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Figure 2.1: Pulmonary Artery Incision. If
patient presents a moderate/severe annu-
lus hypoplasia (< −2 Z value) or a persis-
tent high gradient after valve sparing de-
compression a monocusp reconstruction is
performed.
Figure 2.2: Ventriculotomy. The incision
is carried out as long as necessary to al-
leviate the infundibular narrowing, with a
mean length of 1–2cm.
Figure 2.3: Monocusp creation. A cusp
is fashioned from a PTFE membrane or
autologous pericardium and placed in the
ventricular portion of the opening to allow
it to flush along ventricular walls, there-
after the cusp is cut to the precise patient
outflow dimensions. The monocusp must
be longer for a patient with a longer ven-
triculotomy.
Figure 2.4: Monocusp insertion. The
monocusp is sutured to the ventriculotomy
opening with running 6-0 PTFE suture.
The suturing begins at the proposed hinge
point and extends onto the epicardial sur-
face of the ventricle with bites that in-
clude at least one-half the depth of the my-
ocardium.Care is taken to ensure that the
superior edge of the monocusp matches
that of the retained posterior leaflets
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Figure 2.5: Outflow Tract Patch. The patch forms a roof over the monocusp. This patch is
sutured to the main pulmonary artery and to the ventriculotomy edge and in effect reinforces
the suture line of the monocusp itself to the ventriculotomy. The dotted line in the mid-
portion of this illustration shows the location of the monocusp within the PTFE outflow tract
patch
Figure 2.6: Monocusp Function. The functional characteristics of the monocusp are demon-
strated here. The illustration on the left shows the monocusp in diastole. Blood from the
pulmonary artery has filled the monocusp and presses it against the septum and remaining
posterior pulmonary valve leaflet. This is the coaptation site of the monocusp. In the il-
lustration to the right, the monocusp is in the open position; this would be during systole.
The monocusp is flush with the RVOT anterior RV wall and PTFE outflow tract patch. The
function of the monocusp can be evaluated intraoperatively with transesophageal echocardio-
graphy.
Figures reproduced from CTSNet Website at url:
http://www.ctsnet.org/sections/clinicalresources/congenital/expert tech-1
2.2 Allograft Conduits
Cryopreserved pulmonary allografts were the “gold standard” in the United
Stases from mid-1980s to up to late 1990s (Forbess et al., 2001; Dearani et al.,
2003; Bando et al., 1995) favored over aortic allografts (see Fig. 2.7), being the
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latter prone to calcification and disfunction (Perron, Moran, Gauvreau, & et al.,
1999). In fact, high elastine content of aortic allograft increase their calcification
and adherence propensity, hence making their removal or revision challenging.
Allograft Conduits (ACs) are frequently prone to early significant valve re-
gurgitation or to late conduit stenosis consequent to its shrinkage (Wells et al.,
2002), however their use in Ross operation represent an exception to this be-
haviour since their performance and longevity are greatly increased. This latter
case is probably related to an usual patients older age and the allograft inser-
tion in orthotopic position, which probably reduces the turbulence normally
observed in extracardiac conduits.
Durability’s a critical factor in determining prothesis’ choice for pulmonary
valve replacement. Forbes et al. (Forbess et al., 2001) evaluated pulmonary AC
implanted at the same single institution over 14 consecutive years in three sepa-
rate age groups. They demonstrated in univariate analysis that conduit smaller
size (< 14mm), younger aged patients (< 1 year) and truncus arteriosus were
all risk factors for failure, while in multivariate analysis allograft size was the
only predictor. AC Implants positioned through a Ross operation had the best
outcome with a 5 year survival of 94% (Forbess et al., 2001), while non-Ross AC
implants in patients over 10 years of age had a 5 year survival of 76% (Forbess
et al., 2001).
In other authors studies univariate analysis identified younger age, smaller
AC, diagnosis of truncus arteriosus and aortic AC subtype as risk factors for dis-
function and failure, while multivariate analysis identified smaller AC size and
truncus arteriosus diagnosis as risk factors for dysfunction and failure (Brown,
Ruzmetov, Rodefeld, & et al., 2005; Sinzobahamvya et al., 2001; Tweddell et al.,
2000; Bando et al., 1995; Brown et al., 2005; Hawkins, Bailey, Dillon, & et al.,
1992; Yankah, Alexi-Meskhishvili, Weng, & et al., 1995; Niwaya, Knott-Craig,
Lane, & et al., 1999; Bielefeld, Bishop, Campbell, & et al., 2001; Askovich,
Hawkins, Sower, & et al., 2007; Boethig, Goerler, Westhoff-Bleck, & et al.,
2007; Gerestein, Takkenberg, Oei, & et al., 2001).
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Figure 2.7: Aortic Allograft
[Reproduced from: “Leonardo A. Mulinari; Fa´bio B. Navarro; Gustavo K.
Pimente et al.” – The use and midium-term evaluation of decellularized
allograft cusp in the surgical treatment of the tetralogy of Fallot – Rev Bras Cir
Cardiovasc vol.23 no.2 ]
2.3 Bioprothesic Porcine Valved Dacron ConduitsΠ
Π“Richard Jonas” – Choosing the Right Biomaterial
Comprehensive Surgical Management of Congenital Heart Disease
Second Edition, Ed.: CRC Press
Very low density woven Dacron conduits with a glutaraldehyde-treated pig valve
within were introduced in the 1970s (Bowman, Hancock, & Malm., 1974; Car-
pentier, Lemaigre, Robert, & et al., 1969). Their immense logistic advantages,
firstly the possibility of stocking in a complete range of sizes, proved attractive
and therefore in the ensuing decade thousands of Hancock R© and Carpentier-
Edwards R© conduits were implanted. However, unsatisfactory outcome reports
soon appeared (Alfieri, Blackstone, Kirklin, & et al., 1978; Bailey, Kirklin, Barg-
eron, & et al., 1976) since, as could had been predicted from Wesolowski 1963
studies, a pseudointima frequently accumulated rapidly and, moreover, the glu-
taraldehyde tanning of porcine valve resulted in rapid calcification in children
(Geha, Laks, Stansel, & et al., 1979; Williams, Danielson, McGoon, & et al.,
1982). Combination of this two events determined a less than 50% freedom from
failure at 10 years and other than that these early bioprothesic conduits were
too rigid and large to be successfully applied in neonates and small infants, with
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major risk of stent coronary artery compression. However, it should be noted
that, after successful implantation, their mode of failure was only very rarely
catastrophic and simple monitoring of the systolic murmur and RVH at ECG
allowed elective replacement of these conduits, moreover balloon dilatation of
stenotic valve usually let to lengthen implantation duration. By the mid-1980s
superior results of Ross and others with allografts (Shabbo, Wain, & Ross., 1980;
Kay & Ross., 1985) let these once again to become the conducts of first choice,
even nowadays have been a resurgence of interest in porcine valve Dacron con-
duit, particulary as replacement conduit in the adult-sized teenager or adult.
Figure 2.8: Hancock R© Figure 2.9: Carpentier-Edwards R©
2.4 Bovine Jugular Venus Valved Conduit
Limited availability and durability of ACs, especially for lower sizes, in patients
with CHD and who don’t undergo Ross Aortic Valve Replacement procedure
(Ross-AVR) operation have pushed forward the research of new and alterna-
tive prothesis. In 1999 the Contegra R© Bovine Jugular Vein Conduit (BJVC)
was introduced as an alternative to allografts in RVOT reconstruction and it
represents a low-pressure, glutaraldehyde fixed section of bovine jugular vein
(12–15cm in lenght and 12–22mm in diameter) with three-cusp naturally occur-
ring valves located centrally, each provided with natural sinuses. The conduit
wall is compliant with excellent saturability.
Early animal studies (Ichikawa, Noishiki, Kosuge, & et al., 1997; Scavo-Jr,
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Turrentine, Aufiero, & et al., 1999) reported excellent results, with good leaflet
preservation and freedom from structural degeneration and valve regurgitation
at 3 years, moreover Herijers and colleagues reported resistance to calcification
of Contegra BJVC implanted in sheep, even for just 5 months (Herijgers, Ozaki,
Verbeken, & et al., 2002).
These animal studies have been confirmed by early human clinical trials
with up to 27 months of follow-up reported by Breymann and colleagues, whom
evidenced Contegra BJVC as a promising allografts alternative, and by a re-
port from Bove and colleagues (Bove, Demanet, Wauthy, & et al., 2002) that
compared a modified bicuspid pulmonary allograft with Contegra BJVC and
supported these findings. Specifically the Contegra BJVC, respectively to AC,
demonstrates several advantages: better hemodynamic, greater shelf availabil-
ity, natural continuity between valve and conduit and no requirement for prox-
imal extension.
Contegra R© BJVC insertion includes: 1) 5 minutes conduit rinsing with con-
tinuous manual agitation in four 500-cc baths into regular Saline or Ringer’s
lactate; 2) conduit positioning into main and left PA to avoid sternal compres-
sion; 3) conduit outflow end is cutted so as placing valve conduit as far distally
as possible, near the PA bifurcation, to avoid valve distortion with sternal com-
pression (Sinzobahamvya et al., 2001); 4) Conduit inflow end is spatulated and
sewn with continuous monofilament suture to the right ventriculotomy without
additional prosthetic material. Contegra R© has been approved for Humanitarian
Device Exemption (HDE) in United States in November 2000 and more than
17000 have been implanted and meanwhile European investigators have pub-
lished their results as well (Brown et al., 2005; Dave, Kadner, Bauersfeld, & et
al., 2003; Breymann, Thies, Boethig, & et al., 2002; Bove et al., 2002; Brown,
Ruzmetov, Rodefeld, & et al., 2006; Corno, Hurni, Griffin, & et al., 2002; Car-
rel, Berdat, Pavlovic, & et al., 2002; Chatzis, Giannopoulos, Bobos, & et al.,
2003; Rastan, Walther, Daehnert, & et al., 2006; Morales, Braud, Gunter, & et
al., 2006; Sekarski, van Meir, Rijlaarsdam, & et al., 2007).
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In authors series, during 11 years of follow up, no Contegra BJVC shrinkage
has been evidenced using echocardiography, and explantation rate, the most
stringent measure of performance, has been significantly better at 5 and 10
years compared with allografts (Fiore, Rodefeld, Turrentine, & et al., 2010), be-
ing their experience comparable with a recent work of Boething and colleagues,
who demonstrated a freedom from explantation of 90% at 5 years (Boethig,
Thies, Hecker, & et al., 2005).
Seen these evidences, although longer-term follow-up will better determine
actual conduit durability, this conduit represents the authors’ prothesis of choice
in neonates, infants and young children for RVOT reconstruction, with the ex-
ception in Ross-AVR patients over 5 years of age, where allograft are preferred
(Brown et al., 2006).
On the basis of these facts Contegra BJVC can be considered a promising
alternative for RVOT reconstruction compared with AC pulmonary conduits
for several reasons: early better hemodynamic and long term functional per-
formance, more readily availability in smaller sizes, valve localization within
the conduit which permits proximal infudibular anastomosis without adding
prothetic material and the cost of bovine jugular valve that is nearly one half
of many ACs.
Figure 2.10: Intraoperative picture of an implanted Contegra R©
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2.5 Percutaneous Pulmonary Valves
In January 2010 the Melody R© (MedtronicTM), stented bovine jugular venous
valved RV-PA conduits to be placed percutaneously via venous access, were
released in the United States and its initial results are promising, even with
short follow-up.
Figure 2.11: Melody R© Valve
2.6 Nonvalved Right Ventricular to Pulmonary
Artery Conduits
Non valved RV-PA conduits are still used in some centers with early satisfac-
tory results, however many patients develop late RV dilatation within 10 years.
Derani and colleagues reported on 126 nonvalved RV-PA conduits and concluded
that freedom from failure was the same as with valved conduit (Dearani et al.,
2003), hence they don’t use them no more, nor the authors do as well.
2.7 Stented and Stentless Xenograft Valves in
the Right Ventricular to Pulmonary Artery
Position
The optimal prothesis to implant in young adults (over 18 years) and adults
is still debated, considering that Contegra BJVC is not a feasible option (US
restriction due to HDE category).
Basing on Brown et al.works, authors consider porcine aortic bioprothesis
as an ideal choice for older teenagers (over 18 years) and young adults with
39
congenital abnormalities of the RVOT, especially if they require reintervention
(Brown, Ruzmetov, Yurdakok, & et al., in press), with the recommendation
to use a stentless valve if a size ≥ 25mm stented valve cannot be implanted.
Their implantation technique for stented valves is to locate them in situ in the
RVOT as distally as possible and to roof them over with a small gusset of bovine
pericardium if necessary, while for stentless porcine valves is to resect a short
section of conduit or native Pulmonary Artery (PA) and place the valve in situ
with end-to-end proximal and distal suture lines to eliminate turbulence as much
as possible.
2.8 Mechanical Valves in Pulmonary Position
Mechanical valves have been used for pulmonary valve replacement only in a
few centers (Horer, Vogt, Stierle, & et al., 2009; Haas, Schreiber, Horer, & et al.,
2005) with most of them recommending relatively large doses of Warfarin (INR
3.5-4.5); nevertheless several cases of thromboses have been reported. Authors
have used just three mechanical valves in their series of 800 pulmonary valve
replacements, considering this option only for patients who already carry a
mechanical valve and therefore use Warfarin.
2.9 Bioengineered Valved Conduits for Right
Ventricular Outflow Tract Reconstruction
Bioengineered valved conduits hold promise for RV-PA reconstruction; they are
constructed with biologic or biodegradable scaffold which are being populated
by host cells after the implantation even causing, in some cases, the scaffold to
disappear.
Gottlieb and colleagues demonstrated autologous, engineered tissue, valved
conduits that function well at implantation, and monitored dimensions and
functions in real-time (Gottlieb, Kunal, Emani, & et al., 2010). They evidenced
an in-vivo structural and functional remodelling without stenosis but worsening
of PI after 6 weeks, insights that might be useful for future iterations of engi-
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neered heart valves (Gottlieb et al., 2010).
Critical to current approaches to tissue-engineered heart valves is scaffold
design, which must provide immediate function together with stress transfer to
the new extracellular matrix.
2.10 When to Operate for Right Ventricular
Outflow Tract Dysfunction
RVOT disfunction, either in children and adults, is defined as moderate out-
flow obstruction (> 40mmHg) and/or greater than moderate (2+) PI. Patients
with less than moderate dysfunction may remain asymptomatic or mildly symp-
tomatic for many years, but detecting dysfunction before symptoms occur is
increasingly becoming evident since RV recovery may be incomplete if recon-
struction is performed late. Specifically, preintervention RV volumes are crucial,
since independently associated with RV remodelling, and normalization can be
achieved when pre-operative RV End-Diastolic Volume (EDV) is < 160ml/m2
or End-Sistolic Volume (ESV) is < 82ml/m2 (Oosterhof, van Straten, Vliegen,
& et al., 2007).
The indication for intervention on dysfunctional RVOT are controversial, but
patients with significant RV failure symptoms and objective evidence of RVOT
dysfunction should undergo reintervention. Symptoms include palpitations, de-
creased exercise tollerance and fatigue, while signs include ascites, peripheral
edema, atrial and ventricular arrhythmias, decreased RV ejection fraction, tri-
cuspid valve insufficiency, RV EDV progressive increase and eventually LV dys-
function.
Echocardiography accurately defines pulmonary stenosis entity but it’s less
accurate in quantify pulmonary regurgitation and/or RV dilatation degree, which
are instead markedly more accurately defined by CMR.
Indications for intervention on a dysfunctional RVOT are evolving but now
include patients with moderate to severe PI and/or stenosis ad any of the fol-
lowing problems (Quintessenza et al., 2010; Frigiola, Tsang, Nordmeyer, & et
41
al., 2008; Gerestein et al., 2001):
1. Exertional symptoms of New York Heart Association class II or
greater;
2. Decreased performance capacity on exercise testing;
3. Significant RV dilatation (> 150ml/m2 by CMR);
4. A RV/LV volume ratio > 1.5 in symptomatic patients and ≥ 2 in
asymptomatic patients;
5. Pulmonary regurgitation fraction > 35% on CMR or 3+ on echocar-
diography
6. RVOT gradient above 65mmHg
7. Significant RV dysfunction;
8. Atrial or ventricular arrhythmias;
9. QRS duration > 180ms.
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Chapter 3
“Fondazione Monasterio”
experience with Hancock R©
conduits in Tetralogy of
Fallot late repair
The Introduction in this work describes embryological, anatomical and clinical
features of Tetralogy of Fallot together with a brief discussion on its surgical
correction and a generical description of all the available solutions for the RVOT
reconstruction. In our study we focus exclusively with performances and out-
comes of the RVOT reconstruction with Hancock R© conduits in patients with
Tetralogy of Fallot previously operated for complete surgical repair. Data and
results of the study have been obtained by the retrospective evaluation of these
group of patients to define short-term and long-term outcomes of conduit im-
plantation.
3.1 Patients and Methods
3.1.1 Patients Characteristics
Between February 2003 and May 2015, 32 patients with an early repaired Tetral-
ogy of Fallot, 23 males and 9 females, underwent RVOT reconstruction with
Hancock conduit at Fondazione Toscana “G. Monasterio” Pediatric Cardiac
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Surgery department, Massa, Italy. They underwent to 32 first implantations and
2 conduit replacement due to its failure. Patients mean age was 17, 6 ± 11, 32
years with a minimum of 13 months and a most of 41 years and 8 months;
specifically 12 (35,3%) were less than 12 years of age, 6 were between 12 and
16 years (17,64%) and 16 were over 16 years of age (47,05%). Their physical
features included a mean Body Surface Area (BSA) of 1, 4 ± 0, 54m2 (0,34 m2
minimum and 2,12 m2 most), mean height of 148, 1±33, 6 cm (61 cm minimum
and 195 cm most) and a mean weight of 49, 5±26, 35 Kg (6,9 Kg minimum and
96 Kg maximum).
As defined by this study at the moment of intervention all the patients had
already had a previous RVOT reconstruction procedure as step in ToF correc-
tion, all specified in Table 3.1. It’s significant that Hancock R© implantation
was not performed in first instance in the management of RVOT reconstruc-
tion, in patients with ToF. In fact the 32 patients with ToF successively treated
with Hancock R© implantation mostly (75%) had a RVOT reconstruction with
a patient-tailored autopericardium transannular patch, while in a minority the
RVOT reconstruction was by homograft, xenograft and mechanical valve con-
duit.
The reason for which we don’t normally implant an Hancock R© conduit as
first line solution in patients with ToF is mainly related to the patient early age
at first intervention and the conduit behaviour.
Regarding the former, the usual very early age at first intervention is often
imposed by the necessity of an immediate correction of tetralogy of Fallot, in
which the use of transannular patch represents the optimal technical solution for
very restricted pulmonary annulus. Moreover, nowadays the RV disfunction late
after ToF correction, despite frequent, is unpredictable because of the possibility
of a restrictive physiology. The restrictive physiology is normally present when
a late-diastolic pulmonary blood flow is evident on echocardiography (even pos-
sibly boundary conditions can contribute to it), due to a right atrial pressure
that overrides the main pulmonary pressure. On short term it represents an
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Previous RVOT Reconstructions Number
Total Reconstructions 32
with transannular patch 28
with homograft 2
with xenograft 1
with mechanical valve conduit 1
Table 3.1: Prior first-line RVOT Reconstruction Procedures
adverse hemodynamic event since causes, in the absence of significant residual
VSD or obstructive lesions, a low cardiac output, fluid retention, ascites, pleural
effusions and an increased central venous pressure. Nonetheless, its presence is
advisable since the anterograde diastolic flow contributes to augment total pul-
monary anterograde flow and limits diastolic regurgitation, further improving
total forward cardiac output. On long term the restrictive RV physiology is
even more of crucial importance, explaining the reasons for which the affected
patients have a better long-term outcome after surgical repair. A stiff poorly
compliant right ventricle fail to have the otherwise normal adverse remodelling,
resulting in a smaller heart and RV, hence determining a shorter QRS value
with a lower incidence of arrhythmias. Moreover they present a better exercise
tolerance, presumably because of the limiting effects of restrictive physiology on
PI (Redington, Arsdell, & Anderson, 2009).
Considering the conduit behaviour it is not advisable to implant it during an
early complete correction because of its tendency to degenerate (calcification),
which limits the duration of its function. Furthermore an inevitable mismatch
will occur due to the growth of the child without a consequent growth of the
conduit. Degeneration is especially evident among younger infants in which
the calcium metabolism is sharply increased, due to the growth requirements,
further accelerating conduit calcification. In addition, the sooner a conduit is
implanted, the earlier will be reached the mismatch between conduit diameter
and patient expected pulmonary diameter (and hence the necessity of an earlier
replacement). Therefore it’s rational to delay its implantation to delay a future
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reintervention.
3.1.2 Surgical Considerations
Surgical Indication
Hancock R© conduit placement in patients with an early repaired ToF is the con-
sequence of their primary repair failure, which can affect up to 25% of operated
patients. This event can manifest with several different patterns:
• Symptoms of right heart failure or altered cardiac exercise stress test
• RV or evidence of RV dysfunction, especially if PI is present
• Clinically significant arrhythmias (atrial or ventricular)
• Progressive aneurysmal dilatation of an RVOT patch
• Onset or progression of Tricuspid Regurgitation (TR)
• Residual VSD with shunt > 1, 5 : 1
• Residual patent aorto-pulmonary shunts leading to LV volume overload
• Residual RVOT stenosis
Table 3.2 specifically consider the failure causes of the previously performed
RVOT reconstructions among the 32 patients who required reintervention.
In addition, we have recently introduced as a reference for surgical indication
to Hancock R© re-implantation, currently studied and applied only the patients
with ToF, the Right Ventricle end-diastolic Volume index measured with CMR.
When referring to this parameter, we consider by definition the cut-off for a
correct surgical timing an RVEDVi value over 140− 170ml/m2; however it had
not been always strictly applied, occasionally waiting for values even over 170−
200ml/m2 (Oosterhof, van Straten, et al., 2007; van Huysduynen et al., 2005),
since we and others consider fot this purpose also patients’ echocardiographical
conduit parameters and clinical features for making the decision.
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Hancock R© Conduit Selection
The selected valved conduit must satisfy anatomical and physiological patient
needs, usually favouring, especially in younger infants, a lager graft which pro-
duces a lower gradient with an higher cardiac flow, delaying the reoperation
time for conduit replacement. The 34 adopted conduits had 22 ± 3, 61 mm as
mean diameter, with a minimum of 14 mm and a most of 25 mm; Table 3.3
accurately shows diameters distribution per age. The best suitable conduit per
patient was chosen considering the expected pulmonary valve annulus physio-
logical diameter, which was retrospectively determinable in all cases. It had
a mean value of 20, 5 ± 4, 49 mm with a minimum of 11,8 mm and a most of
26,32 mm. This value was than related to available conduit diameters in order
to define the conduit diameter-pulmunary valve annulus diameter ratio (mean
value 1, 1 ± 0, 12, 0,9 minimum and 1,4 most), the actual parameter used to
decide the diameter’s conduit eventually employed.
The Figure 3.1 evidences the distribution per age of chosen conduits refer-
ring to their ratio. The graph clearly demonstrates our tendency in oversizing
Figure 3.1: PA–Conduit diameter ratios related to patients age
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conduit size relatively to the expected PA annulus in younger patients, particu-
larly under 10 years of age, with the aim to reduce either the impact of patient
growth and the RV-PA gradient after implantation, therefore delaying conduit
failure and moment of mandatory surgical replacement.
Surgical Data and Technique
Conventional continuous bicaval cardiopulmonary bypass was used in 16 proce-
dures, in which median sternotomy or re-sternotomy was considered reasonably
safe. Instead, in 4 patients we isolated femoral vessels as safety measure, even
cannulation was not eventually needed, while in 14 were cannulated, being ster-
notomy considered at risk in damaging major vessels with the risk of intractable
bleeding. Globally the mean CPB duration was 165 ± 69, 02 minutes, with a
minimum of 78 and a most of 419 minutes, while myocardial protection, was
obtained in 16 cases. Specifically the protection was obtained with anterograde
blood cardioplegia in 14 cases and with custodiol anterograde cardioplegia in 2,
whilst no cardioplegia was used in remaining 12 cases being the procedure per-
formed on beating heart. Aortic crossclamp had a mean duration of 98, 5±35, 00
min (minimum 51 and most of 193 minutes), while hypotermia was the rule,
spacing from a minimum value of 15 to a maximum of 32 C◦ and with a mean
of 28±4, 46 C◦. Specifically when we performed the surgical procedure on beat-
ing heart the temperature was 32 C◦, while when we performed the procedure
with aortic crossclamp was 28 C◦ or lower.
The intraoperative conduit placement (see Fig. 3.2) begins with the identifi-
cation of the inflow and outflow aspects of the conduit and a green suture, sewn
on distal extremity indicating the flow direction, makes this procedure easier.
After that, the conduit must be cut to the desiderated length, in accordance to
the patient specific anatomical features and preferred anastomosis angle, while
the extremities must be tailored for the anastomoses. Belli and colleagues (Belli,
Salihog˘lu, Leobon, & et al., 2010) in most cases removed the metallic ring to
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Figure 3.2: Surgical Hancock R© implantation technique
[Reproduced from “Paolo de Siena; Mohamed Ghorbel; Qiang Chen; Deana
Yim; Massimo Caputo” – Common Arterial Trunk – Expert Rev Cardiovasc
Ther. 2011;9(12):1527-1538 ]
avoid potential compression of cardiac structures and cut conduit closely to
the top of commissures to place the valve as far distally as possible, the latter
also did by Champsaur et al.(Champsaur et al., 1998), while Ru¨ffer et al. (Ru¨ffer,
Wittmann, Potapov, & et al., 2012) left the metallic ring in place in all patients.
In our technique the decision is always to leave in place the metallic ring and
to implant the conduit with the valve as far as possible at the pulmonary bifur-
cation. Before the implantation the conduit’s valve must be accurately cleaned
with saline solution, to remove glutaraldehyde from conduit’s surface. The graft
is implanted using separate pledgets stitches on the ventricular aspect and with
a continuous running 4/0 prolene suture on the pulmonary distal anastomosis.
Normally all the dilated pericardial patch, previously used during the early total
correction, is removed and the border of ventriculotomy are inspected to remove
thin dilated muscular tissue.
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In between the 34 surgical interventions for RVOT reconstruction 22 as-
sociated procedures were made, occasionally more than one per intervention.
The most frequently performed procedure was the pulmonary branches recon-
struction, encompassing with this all forms of pulmonary branches reconstruc-
tion (right, left or both) and/or bifurcation plasty, variably accomplished using
autopericardium, bovine/porcine pericardium or prothetic patches (Dacron or
PTFE); all others procedures are listed in Table 3.4.
Before cardiac electrodes placement and sternal closure we usually perform a
transepicardial echocardiography together with an invasive measurement of RV
pressure to immediately evaluate the post-implantation conduit function and
the related cardiac performance.
Postoperative Evaluation
All the patients, during the post-operative hospital stay after the intervention,
underwent seriated echocardiographic evaluations to measure the actual immedi-
ate surgical results. RVOT peak gradient, RV mean pressure and PA regurgita-
tion were measured to determine conduit function, together with the searching
for VSD persistence and possible residual shunt. Moreover, as completion, when
feasible, mitral, tricuspid and aortic valves functioning were studied.
As integration a control CMR, when possible, was performed. This specific
evaluation, as previously already stated, had been reserved for patients with
ToF and surgically corrected RVOT defect. The aim of this study was to de-
termine the RVEDVi after the surgical procedure to compare its value to the
pre-operative measure, as parameter for RV outflow surgical correction effec-
tiveness.
3.1.3 Follow-up
In 27 cases, excluded patients referred back to the cardiologists of the coun-
try of origin, patients underwent follow-up after intervention, whose schedule
consisted in 1st, 3rd, 6th and 12th months echocardiographic evaluation dur-
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ing first year after surgical intervention, followed by yearly recurring controls.
These controls were made directly at our center or by the referring pediatric
cardiologist. These 27 cases were followed for a mean period of 31, 6 ± 34, 42
months, with a peak of 8 years.
Echocardiographic follow-up aimed to determine conduit fuctioning by eval-
uating possible presence of either conduit stenosis or insufficiency. The former
was studied by measuring both the speed flow through the conduit and the RVOT
peak gradient, while the latter by determining regurgitation jet, with colour flow
doppler, and the possible presence of pulmonary ventricle dilatation with its
entity.
Stenosis was graded as follows (Baumgartner, Hung, Bermejo, & et al., 2009):
1. Mild: peak velocity < 3 m/s and peak gradient < 36 mmHg
2. Moderate: peak velocity 3− 4 m/s and peak gradient 36− 64 mmHg
3. Severe: peak velocity > 4 m/s and peak gradient > 64 mmHg
Insufficiency was graded as follows (Baumgartner et al., 2009):
1. Trivial
2. Mild
3. Moderate
4. Severe
In addition to conduit study, on echocardiographic follow-up RV contractility
and AV and aortic valves functioning were also evaluated.
51
Failure of Previous <12 yrs 12–16 yrs +16 yrs Total
RV-PA Reconstruction (n.12) (n.6) (n.16) (n.34)
Stenosis 3 (25%) 1 (16,6%) 4 (25%) 8 (23,52%)
Insufficiency 7 (58,3%) 5 (83,3%) 12 (75%) 24 (70,58%)
Combined 2 (16,6%) 2 (5,88%)
Table 3.2: Causes of previous RVOT reconstruction failure
Conduit <12 yrs 12–16 yrs +16 yrs Total
Diameter (n.12) (n.6) (n.16) (n.34)
14 mm 2 (16,66%) 2 (5,88%)
16 mm 3 (25%) 3 (8,82%)
18 mm 3 (25%) 3 (8,82%)
20 mm 1 (8,33%) 1 (2,94%)
22 mm 2 (16,66%) 3 (50%) 4 (25%) 9 (26,47%)
25 mm 1 (8,33%) 3 (50%) 12 (75%) 16 (47,05%)
Table 3.3: Conduit diameters per age distribution
Associated Procedure Total
Pulmonary branches reconstruction 10
Tricuspid plasty 8
Residual IVD closure 1
Maze procedure 1
Aortic valve plasty 1
Monocusp RVOT reconstruction previous attempt 1
Table 3.4: Surgical associated procedures
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3.2 Results
3.2.1 Early results and patient survival
Patients mean hospital stay was 17, 2 ± 6, 86 days while mean postoperative
period duration was 13, 8 ± 6, 46 days with a minumum of 2 and a most of 40
days for the latter.
Two patients died in hospital after surgical intervention (a 30 days mortality
of 6,25% after 34 surgical procedures), one for low cardiac output syndrome and
one for intraoperative adverse event (massive air embolism due to extracorporeal
circulation accident). In three patients a re-intervention was imposed by an
adverse event and the causes were cardiac tamponade for 2 patients and aortic
valve insufficiency in 1 patient. No conduit-related complications were observed
during patients hospital stay.
Hancock R© conduit performance on early post-operative evaluation
RVOT peak gradient and RV pressure. Patients presented before inter-
vention, regardless of surgical indication for implantation, with a mean RVOT
peak gradient, determined with pre-operative transthoracic echocardiography, of
60, 4± 30, 06 mmHg (with minimum 18 and maximum 111 mmHg). The same
parameter, evaluated with seriated transthoracic echocardiography during post-
operative period before discharge, had a mean value of 29, 1±11, 48 mmHg with
a most of 60 mmHg. In Table 3.5 this is illustrated, with age specification.
RV pressure was determinated with echocardiography pre-operationally, con-
sidering both first conduit implantation and replacement, with a mean value of
53, 3 ± 27, 73 mmHg, and post-operationally with mean value of 41, 6 ± 12, 71
mmHg. Detailed per age values are available in Table 3.5.
RV end-diastolic volume index. The RVEDVi was calculated both be-
fore and after the surgical correction, when feasible, through cardiac RMI.
Pre-operational RVEDVi was available for 18 patients with a mean of 218, 3±
53
57, 94ml/m2, a most of 380ml/m2 and a minimum of 109ml/m2, while post-
operational RVEDVi was available for 9 patients with 126, 1± 14, 49ml/m2, as
mean, 143ml/m2 as most and 103ml/m2 as minimum. Detailed per age values
are available in Table 3.5.
Figure 3.3: Effect of Hancock R© conduit on RVEDVi
The Figure 3.3 shows all the available values both pre- and post-surgical
intervention. From it we can infer the mean value of RVEDVi values differ-
ences for the 8 patients for whom the pre- and post-operational values where
available, which was 81, 42± 30, 08ml/m2, and also the surgical cut-off value is
highlighted.
Pulmonary artery insufficiency. Pulmonary regurgitation jet sever-
ity was evaluated pre- and post-operatively through echocardiographic color-
doppler study based on above criteria (see page 51). Regardless from surgical
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indication we evidenced the values specified on page 55 (per age detailed results
are in Table 3.6).
Pre-operational jet regurgitation severity:
• 0 (absent): 0 patients
• 1 (trivial): 11 patients
• 2 (mild): 2 patients
• 3 (moderate): 6 patients
• 4 (severe): 15 patients
• Total: 34 measures
Post-operational jet regurgitation severity:
• 0 (absent): 6 patients
• 1 (trivial): 28 patients
• 2 (mild): 0 patient
• 3 (moderate): 0 patient
• 4 (severe): 0 patients
• Total: 34 measures
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RV parameter < 12 yrs 12–16 yrs +16 yrs
Mean RVOTpg Preoperative
(mmHg) 74, 5± 28, 93 70 42, 85± 28, 95
Postoperative
30, 1± 14, 08 30, 33± 6, 62 27, 76± 11, 70
Mean RV pressure Preoperative
(mmHg) 69, 14± 27, 17 32, 5± 6, 45 51± 28, 3
Postoperative
45, 44± 15, 66 40± 8, 66 39, 16± 11, 24
Mean RV end-diastolic Preoperative
volume index (ml/m2) 130± 29, 69 210, 8± 27, 09 237, 76± 57, 47
Postoperative
126 119, 66± 20, 81 130± 12, 38
Table 3.5: RV pressures and volumes values per age distribution
PA regurgitation < 12 yrs 12–16 yrs +16 yrs
Pre-operative
None 0 0 0
Trivial 8 3 3
Mild 1 0 1
Moderate 1 1 4
Severe 3 4 8
Post-operative
None 1 1 5
Trivial 12 7 13
Mild 0 0 0
Moderate 0 0 0
Severe 0 0 0
Table 3.6: PA insufficiency values per age distribution
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3.2.2 Late results
Follow-up duration and status
The follow-up mean duration was 31, 6± 34, 42 months with a minimum of 2,39
and a most of 100,92 months, this considering exclusively the 27 patients who
were not lost during the observation period. Per age detailed FU means spans
are listed in Table 3.7.
In 5 patients we observed the Hancock R© conduit failure during follow-up,
which in 4 imposed a percutaneous procedure to try to delay conduit replace-
ment and in 1 a re-implantation surgical procedure for a new device. However,
between the 4 percutaneous procedure 2 had failed and needed thereafter sur-
gical replacement. The mean freedom from conduit failure for this group of
patients was 70, 56± 15, 02 months, with a minimum of 55,15 and a maximum
91,64 months, while their mean age at conduit failure was 6, 86 ± 1, 78 years,
clearly ascribing the event only to conduits implanted in younger patients. Cri-
teria used to define conduit failure were one, or a combination, from: severe
RV-PA peak gradient, severe PI (see page 51), conduit-patient mismatch or
symptoms (see page 41). We clearly evidenced in our series that stenosis and
mismatch represented the causes for the 5 whom underwent Hancock R© failure.
Percutaneous interventions for conduit failure. Between the 5 pa-
tients whose conduits failed, in 4, with stenosis as cause, we decided to try to
delay the re-intervention by submitting them to a percutaneous intervention.
The chosen procedure in 2 cases was the ballooning conduit dilatation, per-
formed 78 months after the primary conduit placement in one patient and after
58 months in the other. Instead, in the remaining 2 patients were implanted a
Medtronic Melody R© valve, in one of them 72 months after conduit implantation,
while in the other after 56 months. In the former group one is still bearing the
original conduit after 45 months from the procedure, while the other had con-
duit failure after 17 months. In the second group one had the valve failure and
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needed reintervention after 38 months from original valve implantation, while
the other is still bearing the functional percutaneously implanted valve after 71
months from implantation.
Hancock R© conduit performance on last follow-up evaluation
The conduit-related RV parameters means obtained during follow-up, which
didn’t included RVEDVi that was not evaluated, are listed in Tab. 3.7, while
PA insufficiency entity, with per age distribution, on Tab. 3.8.
Parameter Global < 12 yrs 12–16 yrs +16 yrs
Mean RVOTpg
45, 3± 26, 02 66, 87± 28, 65 31, 25± 4, 78 32, 33± 14, 59
(mmHg)
Mean RV pressure
53, 6± 18, 8 63, 5± 21, 3 55± 14, 14 44, 44± 13, 56
(mmHg)
Mean FU span
31, 6± 34, 42 52, 77± 37, 56 19, 23± 17, 59 21, 77± 31, 89
(months)
Table 3.7: Pressures and follow-up spanning mean values
PA regurgitation < 12 yrs 12–16 yrs +16 yrs Total
None 0 0 1 1
Trivial 6 4 10 20
Mild 3 0 0 3
Moderate 0 0 0 0
Severe 0 0 0 0
Table 3.8: PA insufficiency values per age distribution
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3.3 Discussion
The Hancock R© is the oldest xenograft biologically valved conduit still available
(Bowmann-Jr, Hancock, & Malm, 1973; Champsaur et al., 1998). It’s initial
spreading was related to the easy availability, due to the wide range of sizes
available, including the smallest which are hard to obtain for an allograft, and
the avoidance of the cryopreservation. However its role, and the enthusiasm
related, had been gradually reduced after the supposed usual inferior mean du-
ration of this kind of conduit, compared to allograft, and the adoption of newer
xenografts, like the Medtronic Contrega R© (Jonas., 2014). The main reasons be-
hind conduit disfunctions are well described in literature and firstly regard valve
degeneration or calcification either causing the development of valvular stenosis
(Belli et al., 2010; Agarwal, Edwards, Feldt, & et al., 1981; Jonas, Freed, Mayer-
Jr, & Castaneda, 1985; McGoon, Danielson, Puga, & et al., 1982). Considering
current literature results the mean conduit durability in patients with ToF and
possibly pulmonary atresia is among the best (including not only xenograft)
between all types of CHDs (Dearani et al., 2003); specifically Champsaur et al
observed an actuarial freedom from re-operation of 93% at 5 years and 80% at
10 years (Champsaur et al., 1998).
Nowadays the Hancock R© application is gradually increasing again and, at
our institution, it has been positioned for CHD in over 100 patients in the last
15 years. Specifically in patients with already palliated ToF, we usually consider
it a saving solution when a first RV-to-PA reconstruction, either from transan-
nular patch or allograft, has failed. In our series of 32 patients the results are
encouraging at present, considering the failure in only 5 patients after more
than 5 years of follow-up. Moreover in four of these patients a percutaneous
procedure (2 ballooning and 2 Melody R© implantation) were made and in 2 of
them this successfully avoid at present the reintervention. In addition we have
clearly evidenced several cornerstone elements regarding the Hancock R© conduit
management criteria together with failure and duration patterns:
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• Delaying as much as possible the conduit implantation, granting an older
patient age at intervention, reduces the mismatch impact issue that in-
evitably develops because of patient’s growth, allowing to move forward
the mandatory conduit replacement.
• When an Hancock R© is necessarily implanted in a younger patient, if it’s
feasible to force a significant conduit oversize, relatively to the expected
per age pulmonary valve annulus, it will be the best long term solution in
terms of conduit duration. In fact, this strategy determines either initial
lower trans-conduit turbulence, with minor impact on conduit degenera-
tion, and delays the moment in which the mismatch between conduit flow
and patient’s physiological stream, because of patient growth, becomes
clear. An heavily oversized conduit often let a long enough graft duration
(even over 10 years).
• Hancock R©, if still permits an adequate stream for patient needs, offer the
feasibility for a percutaneous procedure as save measure for conduit pa-
tency to avoid a newly surgical procedure. This possibility to re-establish
its flow , through ballooning dilatation or stented Melody R© valve implan-
tation inside the conduit, is an actual and peculiar Hancock R© propriety,
which can efficiently reduce re-intervention incidence and has favoured its
newly current usage spreading.
• The stenosis is clearly the main cause of conduit failure being the insuf-
ficiency exceedingly rare due to conduit valve long term efficiency. This
favourably contribute to conduit duration since stenosis development is
gradual and causes conduit failure only on the long term.
In conclusion, the best conduit type to employ in restoring the continuity be-
tween right ventricle and pulmonary artery is still debated, however we consider
the Hancock R© as a valid solution, since, despite the usual necessity to stent or
replace it after a defined period of time, it grants a good duration together with
a good quality of life for patients.
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